Building on translational science from Stanford, Jasper has secured funding to progress its Amgen-licensed conditioning agent for patients awaiting stem cell transplants.
Jasper Therapeutics, a US-based stem cell transplant conditioning agent developer leveraging research from Stanford University and drug producer Amgen, launched on Friday with $35m of series A funding co-led by Qiming Venture Partners USA and Abingworth.
Alexandria Venture Investments, the strategic investment arm of life sciences real estate investment trust Alexandria Real Estate Equities, and Surveyor Capital, an equities unit of asset management group Citadel, also took part in the round.
Jasper Therapeutics is working on antibodies that…
